'Groundbreaking' AbbVie Suits Test Bold Anti-Generic Tactics
Law360 (March 27, 2019, 8:43 PM EDT) -- A trio of trailblazing antitrust lawsuits targeting AbbVie Inc. will force a day of reckoning for some of Big Pharma's most audacious and controversial maneuvers to delay generic and biosimilar competition, experts say.
Three proposed class actions filed in quick succession last week accuse Illinois-based AbbVie of illegally shielding its immunosuppressant Humira — the world's best-selling drug — with a gnarly "thicket" of more than 100 overlapping and unoriginal patents. That accusation raises the remarkable prospect of a court concluding that amassing too much flimsy intellectual property is anticompetitive.
Making matters more dramatic, the suits also allege unlawful "pay-for-delay" agreements to...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!